%0 Journal Article
%T Drug-related pneumonitis caused by amikacin liposome inhalation suspension: One pathologically proven case and single-center experience.
%A Kaneko T
%A Otoshi R
%A Sekine A
%A Baba T
%A Yamada C
%A Haga S
%A Tagami Y
%A Sawazumi T
%A Takemura T
%A Komatsu S
%A Hagiwara E
%A Ogura T
%J Respir Investig
%V 62
%N 4
%D 2024 Jul 13
%M 38615375
暂无%R 10.1016/j.resinv.2024.04.003
%X Amikacin liposome inhalation suspension (ALIS) is known to cause drug-related pneumonitis, which has been described as "hypersensitivity pneumonitis (HP)". However, its clinical and pathological characteristics have never been reported. We retrospectively evaluated 18 patients treated with ALIS. Three (16.7%) patients developed HP-pattern pneumonitis on high-resolution computed tomography. Serum eosinophil counts were elevated up to above 1000/μL in these three patients, which decreased with ALIS discontinuation only. Of note, the specimen obtained by transbronchial lung cryobiopsy in one patient revealed a mild degree of lymphocyte and eosinophil infiltration. Rather, the findings of acute lung injury such as an edematous thickening of the alveolar walls, and an accumulation of foamy degenerative macrophages in the alveolar lumina was prominent. A pulmonary alveolar proteinosis reaction was also observed. HP-pattern pneumonitis due to ALIS may pathologically correspond to acute lung injury and a pulmonary alveolar proteinosis reaction despite increasing serum eosinophil counts.